Irbesartan 是1型血管紧张素II(AT1)受体拮抗剂,IC50为1.3 nM。
Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
1 mg/kg 口服饲喂
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Bernhart CA, et al. J Med Chem, 1993, 36(22), 3371-3380.
分子式 C25H28N6O |
分子量 428.53 |
CAS号 138402-11-6 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 25 mg/mL |
Water <1 mg/mL |
Ethanol 5 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01447797 | Healthy | Drug: HCP0912 / Irbesartan and Atorvastatin | Hanmi Pharmaceutical Company Limited | Phase 1 | 2011-09-01 | 2012-04-01 |
NCT00352560 | Atrial Fibrillation | Drug: Irbesartan|Drug: Placebo | Bristol-Myers Squibb|Sanofi | Phase 3 | 2006-07-01 | 2010-02-15 |
NCT02386293 | Hypertension|Obesity|Stress, Psychological|Blood Pressure | Drug: Irbesartan|Drug: Placebo | Augusta University | Phase 2 | 2014-09-01 | 2016-12-07 |
NCT00265967 | Hypertension | Drug: Irbesartan | Sanofi|Bristol-Myers Squibb | Phase 4 | 2005-09-01 | 2009-12-04 |
NCT00613496 | Persistent Atrial Fibrillation | Drug: irbesartan|Drug: placebo | University of Magdeburg|Sanofi | Phase 4 | 2009-05-01 | 2009-05-28 |
NCT00549133 | Hypertension|Diabetes Mellitus Type 2 | Drug: Irbesartan | Sanofi | Phase 4 | 2003-10-01 | 2007-10-24 |
NCT00987662 | Obesity|Hypertension | Drug: Irbesartan|Drug: Amlodipine | Aristotle University Of Thessaloniki | Phase 4 | 2012-01-01 | 2014-02-10 |
NCT00957554 | Hypertension | Drug: irbesartan/amlodipine|Drug: irbesartan | Sanofi | Phase 3 | 2009-07-01 | 2010-10-25 |
NCT00095394 | Hypertension | Drug: Irbesartan/HCTZ|Drug: Irbesartan monotherapy | Bristol-Myers Squibb|Sanofi | Phase 3 | 2004-09-01 | 2011-04-07 |
NCT00263003 | Hypertension | Drug: Irbesartan/hydrochlorothiazide|Drug: Irbesartan | Sanofi | Phase 3 | 2005-06-01 | 2007-12-06 |
NCT00249795 | Atrial Fibrillation|Cardiovascular Disease | Drug: Irbesartan|Drug: placebo | Sanofi|Bristol-Myers Squibb | Phase 3 | 2003-06-01 | 2010-09-29 |
NCT00564187 | Hypertension | Drug: Irbesartan|Drug: Irbesartan | Sanofi|Bristol-Myers Squibb | Phase 4 | 2003-02-01 | 2007-11-27 |
NCT00095290 | Albuminuria | Drug: Ramipril + Irbesartan|Drug: Ramipril + Placebo | Bristol-Myers Squibb|Sanofi | Phase 4 | 2004-09-01 | 2011-04-07 |
NCT02842359 | Type 2 Diabetes Mellitus | Drug: Irbesartan/atorvastatin fixed dose combination|Drug: Irbesartan SR47436|Drug: Atorvastatin | Sanofi | Phase 4 | 2016-08-01 | 2016-10-19 |
NCT00517322 | Left Atrial Volume|Hypertensive Heart Disease|Antihypertensive Drugs|Diastolic Function|Renin Angiotensin System | Drug: ramipril|Drug: irbesartan | Universit degli Studi dell'Insubria | Phase 4 | 2007-08-01 | 2007-08-15 |
NCT00334581 | Hypertension | Drug: Irbesartan|Drug: Irbesartan | Sanofi|Bristol-Myers Squibb | Phase 4 | 2006-05-01 | 2009-09-14 |
NCT00389168 | Hypertension | Drug: Irbesartan|Drug: Atenolol | Karolinska Institutet|Bristol-Myers Squibb|Sanofi|Swedish Heart Lung Foundation | Phase 2|Phase 3 | 1995-04-01 | 2015-05-03 |
NCT00110422 | Metabolic Syndrome|Hypertension | Drug: Irbesartan|Drug: Hydrochlorothiazide | Bristol-Myers Squibb|Sanofi | Phase 4 | 2005-11-01 | 2011-04-07 |
NCT00095550 | Hypertension | Drug: Irbesartan/HCTZ|Drug: Irbesartan monotherapy|Drug: HCTZ monotherapy | Bristol-Myers Squibb|Sanofi | Phase 3 | 2004-10-01 | 2011-04-07 |
NCT01712100 | Hypertension | Drug: Irbesartan|Drug: Avapro | Roxane Laboratories | 2007-08-01 | 2012-10-19 | |
NCT01712113 | Hypertension | Drug: Irbesartan|Drug: Avapro | Roxane Laboratories | 2007-08-01 | 2012-10-19 | |
NCT00362258 | Hypertension | Drug: Irbesartan (Aprovel) | Sanofi|Bristol-Myers Squibb | Phase 4 | 2006-02-01 | 2011-04-01 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们